ArticlePloS one2018
Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Continuous glucose monitoring in type 2 diabetes: Evidence for glycaemic metrics and patient-reported outcomes.Diabetic medicine : a journal of the British Diabetic Association · 2026Pooled it
- A bibliometric analysis of diabetic gastroparesis from 1979 to 2024.Frontiers in medicine · 2024Pooled it
- Review
- A retrospective observational study evaluating the safety and effectiveness of commercially available automated insulin delivery systems in people with type 1 diabetes and gastroparesis.Diabetes, obesity & metabolism · 2026Observational
- Enhancing Type 2 Diabetes Care With CGM Integration: Insights From an Italian Expert Group.Diabetes/metabolism research and reviews · 2025Review
- Diabetic gastroenteropathy: a pan-alimentary complication.Diabetologia · 2025Review
- Current Concepts in Gastroparesis and Gastric Neuromuscular Disorders-Pathophysiology, Diagnosis, and Management.Diagnostics (Basel, Switzerland) · 2025Review
- Concept analysis of diabetes-related quality of life.Health and quality of life outcomes · 2025Review
- Diabetic gastroparesis: clinical features, diagnosis and management.Irish journal of medical science · 2023Review
- Diet consistency modification improves postprandial glycemic and gastroparesis symptoms.Journal of diabetes and metabolic disorders · 2022Article
- Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Review
- Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series.Journal of diabetes science and technology · 2021Review
- Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM.Journal of diabetes science and technology · 2021Article
- Diabetic Gastroparesis: A Review.Diabetes spectrum : a publication of the American Diabetes Association · 2020Article
- Symptoms Suggestive of Gastroparesis in a Community-Based Cohort of European Americans and African Americans with Type 2 Diabetes Mellitus.Digestive diseases and sciences · 2020Article
- Exposure to recurrent hypoglycemia alters hippocampal metabolism in treated streptozotocin-induced diabetic rats.CNS neuroscience & therapeutics · 2020Article
- Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity.Neurogastroenterology and motility · 2020Article
- Diabetic Gastroparesis and Glycaemic Control.Current diabetes reports · 2019Review
- Diabetic Gastroparesis.Endocrine reviews · 2019Review
- Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions.Neurogastroenterology and motility · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 12 institutions in 1 country.
Funding
Abstract
Erratic blood glucose levels can be a cause and consequence of delayed gastric emptying in patients with diabetes. It is unknown if better glycemic control increases risks of hypoglycemia or improves hemoglobin A1c levels and gastrointestinal symptoms in diabetic gastroparesis. This study investigated the safety and potential efficacy of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in poorly controlled diabetes with gastroparesis. Forty-five type 1 or 2 patients with diabetes and gastroparesis and hemoglobin A1c >8% from the NIDDK Gastroparesis Consortium enrolled in a 24 week open-label pilot prospective study of CSII plus CGM. The primary safety outcome was combined numbers of mild, moderate, and severe hypoglycemic events at screening and 24 weeks treatment. Secondary outcomes included glycemic excursions on CGM, hemoglobin A1c, gastroparesis symptoms, quality-of-life, and liquid meal tolerance. Combined mild, moderate, and severe hypoglycemic events occurred similarly during the screening/run-in (1.9/week) versus treatment (2.2/week) phases with a relative risk of 1.18 (95% CI 0.85-1.64, P = 0.33). CGM time in hypoglycemia (<70 mg/dL) decreased from 3.9% to 1.8% (P<0.0001), time in euglycemia (70-180 mg/dL) increased from 44.0% to 52.0% (P = 0.02), time in severe hyperglycemia (>300 mg/dL) decreased from 14.2% to 7.0% (P = 0.005), and hemoglobin A1c decreased from 9.4±1.4% to 8.3±1.3% (P = 0.001) on CSII plus CGM. Symptom scores decreased from 29.3±7.1 to 21.9±10.2 with lower nausea/vomiting, fullness/early satiety, and bloating/distention scores (P≤0.001). Quality-of-life scores improved from 2.4±1.1 to 3.1±1.1 (P<0.0001) and volumes of liquid nutrient meals tolerated increased from 420±258 to 487±312 mL (P = 0.05) at 24 weeks. In conclusion, CSII plus CGM appeared to be safe with minimal risks of hypoglycemic events and associated improvements in glycemic control, gastroparesis symptoms, quality-of-life, and meal tolerance in patients with poorly controlled diabetes and gastroparesis. This study supports the safety, feasibility, and potential benefits of improving glycemic control in diabetic gastroparesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.